Table 3. Median overall survival for all patients by prognostic factors.
| Variables | No. of events/No. of patients | Median disease-free interval (months)** |
p- value |
|---|---|---|---|
| All patients | 11/25 | 33.1 (15.3–undefined) | |
| Stage | |||
| One | 2/7 | NR(1.3–undefined) | 0.024 |
| Two | 3/3 | 8.1 (8.0–undefined) | |
| Three | 5/13 | 33.1 (11.6–undefined) | |
| Tumor grade | |||
| One | 2/5 | NR (8.1–undefined) | 0.981 |
| Two | 5/10 | 33.1 (8.0–undefined) | |
| Three | 4/10 | 21.8 (1.3–undefined) | |
| Histopathology | |||
| Serous | 4/11 | 33.1 (9.7–undefined) | 0.089 |
| Endometroid | 2/7 | NR(8.0–undefined) | |
| Mucinous | 2/2 | 8.1 (8.1–undefined) | |
| Clear cell | 3/5 | 21.8 (1.3–undefined) | |
| Secondary cytoreduction | |||
| Optimal | 7/20 | NR (15.3–undefined) | 0.348 |
| Suboptimal | 4/5 | 21.8 (9.7–undefined) | |
| Disease-free interval | |||
| <12 months | 2/6 | NR (8.0–undefined) | 0.761 |
| 312 months | 9/19 | 30.6 (11.6–undefined) | |
| Response to secondary cytoreductive surgery | |||
| No* | 4/7 | 11.6 (1.3–undefined) | 0.007 |
| Yes | 7/18 | NR (18.5–undefined) |
**Median (95% CI); NR: Not reached.
*These patients had the progressive disease even after secondary surgery and chemotherapy.